RespireRx Pharmaceuticals Inc. (RSPI)
USD 0.0
(-23.81%)
USD 0.0
(-23.81%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -1.49 Million USD | 35.5% |
| 2021 | -963.75 Thousand USD | 22.8% |
| 2020 | -2.42 Million USD | -90.91% |
| 2019 | -378.52 Thousand USD | 20.22% |
| 2018 | -2.45 Million USD | 48.69% |
| 2017 | -4.24 Million USD | 49.88% |
| 2016 | -8.46 Million USD | -61.78% |
| 2015 | -5.05 Million USD | -20.24% |
| 2014 | -2.58 Million USD | -281.78% |
| 2013 | -1.13 Million USD | 56.31% |
| 2012 | -7.25 Million USD | -21.08% |
| 2011 | -2.14 Million USD | -193.57% |
| 2010 | 2.29 Million USD | 128.7% |
| 2009 | -8.25 Million USD | 46.05% |
| 2008 | -14.43 Million USD | -10.01% |
| 2007 | -12.84 Million USD | 18.5% |
| 2006 | -15.94 Million USD | -38.81% |
| 2005 | -11.49 Million USD | 99.53% |
| 2004 | -2.54 Billion USD | -245659.9% |
| 2003 | -1.03 Million USD | -14.63% |
| 2002 | -901.6 Thousand USD | 59.91% |
| 2001 | -2.24 Million USD | -7393.72% |
| 2000 | -30 Thousand USD | 97.9% |
| 1999 | -1.43 Million USD | 72.77% |
| 1998 | -5.26 Million USD | -7.62% |
| 1997 | -4.88 Million USD | -19.47% |
| 1996 | -4.09 Million USD | 42.38% |
| 1995 | -7.1 Million USD | -42.0% |
| 1994 | -5 Million USD | -733.33% |
| 1993 | -600 Thousand USD | 76.0% |
| 1992 | -2.5 Million USD | 10.71% |
| 1991 | -2.6 Million USD | -13.04% |
| 1990 | -2.3 Million USD | -91.67% |
| 1989 | -1.2 Million USD | -313.79% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | -390.37 Thousand USD | -33.63% |
| 2023 Q3 | -332.5 Thousand USD | 28.62% |
| 2023 Q2 | -465.85 Thousand USD | -19.34% |
| 2022 Q3 | -388.96 Thousand USD | -10.35% |
| 2022 Q2 | -352.47 Thousand USD | 42.87% |
| 2022 FY | - USD | 35.5% |
| 2022 Q1 | -616.95 Thousand USD | -20.1% |
| 2022 Q4 | -292.12 Thousand USD | 24.9% |
| 2021 Q3 | -581.3 Thousand USD | 12.45% |
| 2021 Q4 | -513.68 Thousand USD | 11.63% |
| 2021 FY | - USD | 22.8% |
| 2021 Q1 | -800.14 Thousand USD | 7.57% |
| 2021 Q2 | -663.99 Thousand USD | 17.01% |
| 2020 Q2 | -616.91 Thousand USD | -18.51% |
| 2020 FY | - USD | -90.91% |
| 2020 Q3 | -1.31 Million USD | -112.67% |
| 2020 Q4 | -865.67 Thousand USD | 34.02% |
| 2020 Q1 | -520.57 Thousand USD | -25.8% |
| 2019 Q4 | -413.79 Thousand USD | 3.87% |
| 2019 Q1 | -473.86 Thousand USD | 18.29% |
| 2019 FY | - USD | 20.22% |
| 2019 Q2 | -418.39 Thousand USD | 11.71% |
| 2019 Q3 | -430.45 Thousand USD | -2.88% |
| 2018 Q4 | -579.92 Thousand USD | -15.16% |
| 2018 Q2 | -586.82 Thousand USD | -15.93% |
| 2018 FY | - USD | 48.69% |
| 2018 Q3 | -503.59 Thousand USD | 14.18% |
| 2018 Q1 | -506.17 Thousand USD | 25.97% |
| 2017 FY | - USD | 49.88% |
| 2017 Q2 | -1.54 Million USD | -9.09% |
| 2017 Q1 | -1.41 Million USD | 2.43% |
| 2017 Q3 | -591.57 Thousand USD | 61.78% |
| 2017 Q4 | -683.75 Thousand USD | -15.58% |
| 2016 FY | - USD | -61.78% |
| 2016 Q2 | -2.34 Million USD | 2.78% |
| 2016 Q3 | -2.24 Million USD | 4.26% |
| 2016 Q1 | -2.41 Million USD | -54.9% |
| 2016 Q4 | -1.45 Million USD | 35.3% |
| 2015 Q4 | -1.55 Million USD | 22.84% |
| 2015 Q2 | -1.05 Million USD | -127.93% |
| 2015 Q1 | -464.43 Thousand USD | 32.45% |
| 2015 FY | - USD | -20.24% |
| 2015 Q3 | -2.02 Million USD | -90.86% |
| 2014 FY | - USD | -281.78% |
| 2014 Q2 | -287.52 Thousand USD | 88.08% |
| 2014 Q1 | -2.41 Million USD | -3981.52% |
| 2014 Q4 | -687.58 Thousand USD | 28.72% |
| 2014 Q3 | -964.58 Thousand USD | -235.47% |
| 2013 Q3 | -58.34 Thousand USD | 67.44% |
| 2013 Q1 | -843.21 Thousand USD | -153.48% |
| 2013 FY | - USD | 56.31% |
| 2013 Q4 | -59.1 Thousand USD | -1.29% |
| 2013 Q2 | -179.22 Thousand USD | 78.75% |
| 2012 Q1 | -927.1 Thousand USD | -210.11% |
| 2012 Q2 | -962 Thousand USD | -3.76% |
| 2012 Q3 | -545.17 Thousand USD | 43.33% |
| 2012 FY | - USD | -21.08% |
| 2012 Q4 | -332.65 Thousand USD | 38.98% |
| 2011 Q2 | -339.39 Thousand USD | 77.91% |
| 2011 FY | - USD | -193.57% |
| 2011 Q4 | 841.96 Thousand USD | 174.92% |
| 2011 Q3 | -1.12 Million USD | -231.14% |
| 2011 Q1 | -1.53 Million USD | -60.08% |
| 2010 Q1 | 5.7 Million USD | 497.83% |
| 2010 Q2 | -1.94 Million USD | -134.04% |
| 2010 Q3 | -502.39 Thousand USD | 74.12% |
| 2010 FY | - USD | 128.7% |
| 2010 Q4 | -959.55 Thousand USD | -91.0% |
| 2009 FY | - USD | 46.05% |
| 2009 Q1 | -3.13 Million USD | -0.36% |
| 2009 Q2 | -1.89 Million USD | 39.34% |
| 2009 Q3 | -1.68 Million USD | 11.33% |
| 2009 Q4 | -1.43 Million USD | 14.86% |
| 2008 FY | - USD | -10.01% |
| 2008 Q4 | -3.11 Million USD | 1.85% |
| 2008 Q3 | -3.17 Million USD | 21.78% |
| 2008 Q2 | -4.06 Million USD | 9.93% |
| 2008 Q1 | -4.51 Million USD | -29.35% |
| 2007 Q3 | -3.09 Million USD | -5.04% |
| 2007 Q2 | -2.94 Million USD | 26.41% |
| 2007 Q1 | -3.99 Million USD | -12.0% |
| 2007 FY | - USD | 18.5% |
| 2007 Q4 | -3.48 Million USD | -12.84% |
| 2006 Q1 | -4.68 Million USD | -21.58% |
| 2006 Q4 | -3.57 Million USD | 5.45% |
| 2006 Q3 | -3.77 Million USD | 17.15% |
| 2006 FY | - USD | -38.81% |
| 2006 Q2 | -4.55 Million USD | 2.75% |
| 2005 FY | - USD | 99.53% |
| 2005 Q2 | -2.6 Million USD | 0.45% |
| 2005 Q1 | -2.61 Million USD | -171.93% |
| 2005 Q4 | -3.85 Million USD | -44.76% |
| 2005 Q3 | -2.66 Million USD | -2.15% |
| 2004 Q4 | 3.63 Million USD | 334.82% |
| 2004 Q3 | -1.55 Million USD | -9.3% |
| 2004 Q2 | -1.41 Million USD | -151.93% |
| 2004 Q1 | -562.91 Thousand USD | -351.13% |
| 2004 FY | - USD | -245659.9% |
| 2003 FY | - USD | -14.63% |
| 2003 Q3 | -449.02 Thousand USD | -900.23% |
| 2003 Q2 | -44.89 Thousand USD | 56.74% |
| 2003 Q1 | -103.78 Thousand USD | 56.99% |
| 2003 Q4 | -1.17 Million USD | 72.21% |
| 2002 FY | - USD | 59.91% |
| 2002 Q4 | -241.29 Thousand USD | 62.51% |
| 2002 Q3 | -643.56 Thousand USD | -81.89% |
| 2002 Q2 | -353.82 Thousand USD | 56.45% |
| 2002 Q1 | -812.53 Thousand USD | 13.16% |
| 2001 Q1 | -255.64 Thousand USD | 31.36% |
| 2001 Q2 | -224.25 Thousand USD | 21.49% |
| 2001 Q3 | 1.2 Million USD | 635.31% |
| 2001 Q4 | -935.68 Thousand USD | -177.94% |
| 2001 FY | - USD | -7393.72% |
| 2000 Q3 | -1.32 Million USD | -211.21% |
| 2000 FY | - USD | 97.9% |
| 2000 Q1 | -610.83 Thousand USD | -64.76% |
| 2000 Q2 | 1.18 Million USD | 294.71% |
| 2000 Q4 | -166.17 Thousand USD | 68.54% |
| 1999 Q2 | -430 Thousand USD | -141.35% |
| 1999 Q4 | -370.74 Thousand USD | -55.91% |
| 1999 Q3 | -237.78 Thousand USD | 44.7% |
| 1999 FY | - USD | 72.77% |
| 1999 Q1 | 1.04 Million USD | 230.0% |
| 1998 Q4 | -800 Thousand USD | 33.33% |
| 1998 Q1 | -1.6 Million USD | -14.29% |
| 1998 Q2 | -660.17 Thousand USD | 58.74% |
| 1998 Q3 | -1.2 Million USD | -81.77% |
| 1998 FY | - USD | -7.62% |
| 1997 Q4 | -1.3 Million USD | -7.69% |
| 1997 Q3 | -1.2 Million USD | -121.26% |
| 1997 Q2 | -587.54 Thousand USD | 51.04% |
| 1997 FY | - USD | -19.47% |
| 1997 Q1 | -1.2 Million USD | 7.69% |
| 1996 Q1 | -1.2 Million USD | -9.09% |
| 1996 Q4 | -1.3 Million USD | -18.18% |
| 1996 Q3 | -1.1 Million USD | -277.9% |
| 1996 Q2 | -291.08 Thousand USD | 75.74% |
| 1996 FY | - USD | 42.38% |
| 1995 FY | - USD | -42.0% |
| 1995 Q2 | -2.8 Million USD | -154.55% |
| 1995 Q3 | -800 Thousand USD | 71.43% |
| 1995 Q4 | -1.1 Million USD | -37.5% |
| 1995 Q1 | -1.1 Million USD | 35.29% |
| 1994 Q3 | -1.4 Million USD | 12.5% |
| 1994 FY | - USD | -733.33% |
| 1994 Q4 | -1.6 Million USD | -21.43% |
| 1994 Q2 | -1.6 Million USD | -14.29% |
| 1994 Q1 | -1.3 Million USD | -1500.0% |
| 1993 FY | - USD | 76.0% |
| 1993 Q1 | -100 Thousand USD | -110.0% |
| 1993 Q2 | -300 Thousand USD | -200.0% |
| 1993 Q3 | 100 Thousand USD | 133.33% |
| 1993 Q4 | 100 Thousand USD | 0.0% |
| 1992 FY | - USD | 10.71% |
| 1992 Q1 | 100 Thousand USD | 0.0% |
| 1992 Q2 | -2.6 Million USD | -2700.0% |
| 1992 Q3 | 500 Thousand USD | 119.23% |
| 1992 Q4 | 1 Million USD | 100.0% |
| 1991 FY | - USD | -12.0% |
| 1991 Q1 | 100 Thousand USD | 0.0% |
| 1991 Q4 | 100 Thousand USD | 0.0% |
| 1991 Q3 | 100 Thousand USD | 103.57% |
| 1991 Q2 | -2.8 Million USD | -2900.0% |
| 1990 Q2 | -2.5 Million USD | -2600.0% |
| 1990 FY | - USD | -92.31% |
| 1990 Q3 | 100 Thousand USD | 104.0% |
| 1990 Q4 | 100 Thousand USD | 0.0% |
| 1990 Q1 | 100 Thousand USD | 0.0% |
| 1989 Q4 | 100 Thousand USD | 0.0% |
| 1989 Q2 | -1.3 Million USD | -1400.0% |
| 1989 Q3 | 100 Thousand USD | 107.69% |
| 1989 Q1 | 100 Thousand USD | 0.0% |
| 1989 FY | - USD | -348.28% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 97.89% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 74.719% |
| SQZ Biotechnologies Company | -64.14 Million USD | 97.663% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 91.371% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 101.594% |
| Mesoblast Limited | -62.38 Million USD | 97.598% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 2.418% |
| Genus plc | 73.7 Million USD | 102.034% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 77.329% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 57.742% |
| Marizyme, Inc. | -34.28 Million USD | 95.628% |
| ContraFect Corporation | -64.99 Million USD | 97.694% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 82.913% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 66.884% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -6.927% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 43.319% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 35.498% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -189.338% |
| Accustem Sciences Inc. | -3.74 Million USD | 59.991% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 96.892% |
| EV Biologics, Inc. | -1.26 Million USD | -18.291% |
| Q BioMed Inc. | -617.62 Thousand USD | -142.688% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 141.963% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -137.016% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 34.388% |
| Biomind Labs Inc. | -1.03 Million USD | -44.885% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 115.176% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 79.069% |
| Skye Bioscience, Inc. | -13.54 Million USD | 88.936% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -0.773% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -5895.624% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 61.411% |
| IMV Inc. | -35.52 Million USD | 95.781% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 90.555% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 40.091% |
| GB Sciences, Inc. | -1.41 Million USD | -5.565% |
| Alpha Cognition Inc. | -9.7 Million USD | 84.556% |
| HST Global, Inc. | -5303.00 USD | -28165.246% |
| CSL Limited | 4.78 Billion USD | 100.031% |
| Halberd Corporation | -74.27 Thousand USD | -1917.94% |
| Enzolytics Inc. | -2.12 Million USD | 29.364% |
| Resverlogix Corp. | -11.74 Million USD | 87.235% |
| Affymax, Inc. | -14.29 Million USD | 89.514% |
| SYBLEU INC | -141.57 Thousand USD | -958.766% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 51.064% |
| argenx SE | -216.02 Million USD | 99.306% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 97.291% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 223.164% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 495.653% |
| AVAX Technologies, Inc. | -6.11 Million USD | 75.479% |
| Zenith Capital Corp. | -8.6 Million USD | 82.583% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.397% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -8504.018% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 38.732% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -751.533% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 96.218% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 48.176% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -43.256% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 22391.88% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 14.348% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 21.969% |
| BioStem Technologies, Inc. | -7.55 Million USD | 80.157% |
| ONE Bio Corp. | 13.61 Million USD | 111.011% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -727.722% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 27.131% |
| Agentix Corp. | -1.37 Million USD | -9.269% |
| LadRx Corporation | 412.28 Thousand USD | 463.562% |
| Cell Source, Inc. | -4.27 Million USD | 64.918% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -308.175% |
| Regen BioPharma, Inc. | 1.46 Million USD | 202.248% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -59.977% |
| NovAccess Global Inc. | -1.03 Million USD | -44.85% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 116.93% |
| Itoco Inc. | -1.86 Million USD | 19.801% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -294.844% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -34.311% |
| Kadimastem Ltd | -2.62 Million USD | 42.885% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -526.764% |
| CytoDyn Inc. | -18.02 Million USD | 91.686% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -1796.653% |
| Mobile Lads Corp. | -2.24 Million USD | 33.119% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -12156.979% |
| Qrons Inc. | -40.08 Thousand USD | -3639.692% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -208.621% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 384.189% |
| Rebus Holdings, Inc. | -951 Thousand USD | -57.614% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -41.139% |
| International Stem Cell Corporation | 202 Thousand USD | 842.033% |
| Bioxytran, Inc. | -3.82 Million USD | 60.763% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2747.466% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 39.117% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 95.821% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -3230.902% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 45.255% |
| Neutra Corp. | -181.24 Thousand USD | -726.996% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 92.565% |
| PureTech Health plc | -11.62 Million USD | 87.108% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 92.564% |
| IXICO plc | -707 Thousand USD | -112.009% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 80.496% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 96.9% |
| CSL Limited | 4.73 Billion USD | 100.032% |
| Cellectis S.A. | -92.63 Million USD | 98.382% |